Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Novel therapies for children with severe asthma
Top Ten Searches
hla beta 2 probiotics hypo allergenic scid urticaria aeroallergens asthma angioedema hivYour Article Summary
Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees
Blood, 09/22/09
Varghese B et al. – When a poly–specific T cell response was generated against the tumor by intratumoral CpG, even large established tumors were cured. Such an immune response can prevent the emergence of antibody selected tumor escapees and provide long–lasting tumor protection.
Related Articles
Lymphoma in patients treated with anti-TNF. Results of the 3-year prospective French RATIO registry.
Annals of Rheumatic Diseases, 10/22/09
Relevance Score: 96%
Do male lymphoma survivors have impaired sexual function?
Journal of Clinical Oncology, 10/29/09
Relevance Score: 94%
Subcutaneous ‘lipoma-like’ B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT
Annals of Oncology, 10/29/09
Relevance Score: 94%
Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach
Hematological Oncology, 10/27/09
Relevance Score: 94%
Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211
Journal of Clinical Oncology, 10/12/09
Relevance Score: 93%
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Prioritization of cancer antigens: keeping the target in sight
Expert Review of Vaccines, 12/02/09
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Clinical Cancer Research, 12/01/09
A High-Affinity Fully Human Anti–IL-6 mAb, 1339, for the Treatment of Multiple Myeloma
Clinical Cancer Research, 12/01/09
Sponsor
Article Search
Sponsor


See Latest Articles


